JP2017526620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526620A5 JP2017526620A5 JP2016572433A JP2016572433A JP2017526620A5 JP 2017526620 A5 JP2017526620 A5 JP 2017526620A5 JP 2016572433 A JP2016572433 A JP 2016572433A JP 2016572433 A JP2016572433 A JP 2016572433A JP 2017526620 A5 JP2017526620 A5 JP 2017526620A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- heart failure
- amino acid
- composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 115
- 229920001184 polypeptide Polymers 0.000 claims description 113
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 113
- 206010019280 Heart failures Diseases 0.000 claims description 33
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 26
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 26
- 150000001413 amino acids Chemical group 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 22
- -1 tridecanoyl Chemical group 0.000 claims description 22
- 102000018746 Apelin Human genes 0.000 claims description 20
- 108010052412 Apelin Proteins 0.000 claims description 20
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 125000001931 aliphatic group Chemical group 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 230000001684 chronic effect Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 claims description 11
- 230000000747 cardiac effect Effects 0.000 claims description 10
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 101100411708 Danio rerio rarga gene Proteins 0.000 claims description 8
- 244000191761 Sida cordifolia Species 0.000 claims description 8
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 8
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 102400000252 Apelin-13 Human genes 0.000 claims description 6
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- XXCCRHIAIBQDPX-PEWBXTNBSA-N apelin-13 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)C1=CN=CN1 XXCCRHIAIBQDPX-PEWBXTNBSA-N 0.000 claims description 6
- 108010040480 apelin-13 peptide Proteins 0.000 claims description 6
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 6
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims description 5
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 5
- 230000003205 diastolic effect Effects 0.000 claims description 5
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims description 5
- 150000008574 D-amino acids Chemical class 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 150000001576 beta-amino acids Chemical class 0.000 claims description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 4
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical compound N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 claims description 2
- YQZVQKYXWPIKIX-UHFFFAOYSA-N 2-[2-[2-[[2-[2-(2-aminoethoxy)ethoxy]acetyl]amino]ethoxy]ethoxy]acetic acid Chemical compound NCCOCCOCC(=O)NCCOCCOCC(O)=O YQZVQKYXWPIKIX-UHFFFAOYSA-N 0.000 claims description 2
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims description 2
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 2
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- YSFZWUJOBANROZ-UHFFFAOYSA-N heptylmalonic acid Chemical compound CCCCCCCC(C(O)=O)C(O)=O YSFZWUJOBANROZ-UHFFFAOYSA-N 0.000 claims description 2
- FXHCFPUEIDRTMR-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;chloride Chemical compound Cl.C1=CC=C2CNC(C(=O)O)CC2=C1 FXHCFPUEIDRTMR-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 2
- 239000001273 butane Substances 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010322P | 2014-06-10 | 2014-06-10 | |
| US62/010,322 | 2014-06-10 | ||
| PCT/US2015/035205 WO2015191781A2 (en) | 2014-06-10 | 2015-06-10 | Apelin polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019187458A Division JP2020023539A (ja) | 2014-06-10 | 2019-10-11 | アペリンポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526620A JP2017526620A (ja) | 2017-09-14 |
| JP2017526620A5 true JP2017526620A5 (enExample) | 2018-07-05 |
| JP6803236B2 JP6803236B2 (ja) | 2020-12-23 |
Family
ID=54608924
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572433A Active JP6803236B2 (ja) | 2014-06-10 | 2015-06-10 | アペリンポリペプチド |
| JP2019187458A Pending JP2020023539A (ja) | 2014-06-10 | 2019-10-11 | アペリンポリペプチド |
| JP2021200644A Withdrawn JP2022028961A (ja) | 2014-06-10 | 2021-12-10 | アペリンポリペプチド |
| JP2023210068A Pending JP2024026356A (ja) | 2014-06-10 | 2023-12-13 | アペリンポリペプチド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019187458A Pending JP2020023539A (ja) | 2014-06-10 | 2019-10-11 | アペリンポリペプチド |
| JP2021200644A Withdrawn JP2022028961A (ja) | 2014-06-10 | 2021-12-10 | アペリンポリペプチド |
| JP2023210068A Pending JP2024026356A (ja) | 2014-06-10 | 2023-12-13 | アペリンポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10941182B2 (enExample) |
| EP (3) | EP3155002B1 (enExample) |
| JP (4) | JP6803236B2 (enExample) |
| AU (1) | AU2015274574B2 (enExample) |
| CA (1) | CA2951391C (enExample) |
| ES (1) | ES2950789T3 (enExample) |
| MX (1) | MX370689B (enExample) |
| WO (1) | WO2015191781A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972871A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| US10640545B2 (en) * | 2017-07-03 | 2020-05-05 | The Governors Of The Univ Of Alberta Tec Edmonton | Apelin peptides and uses thereof |
| WO2019023295A1 (en) * | 2017-07-27 | 2019-01-31 | Saint Louis University | Fatty acid modified human epidermal growth factor |
| US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| WO2019229242A1 (en) * | 2018-05-31 | 2019-12-05 | Novo Nordisk A/S | Derivatives comprising an apelin analogue and uses thereof |
| AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| JP2022513626A (ja) | 2018-11-26 | 2022-02-09 | ノバルティス アーゲー | Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド |
| WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| KR20220027215A (ko) * | 2019-07-01 | 2022-03-07 | 발리터 인코포레이티드 | 다가 펩티드 컨쥬게이트를 위한 친수성 링커 |
| WO2021030687A1 (en) * | 2019-08-15 | 2021-02-18 | Cohbar, Inc. | Therapeutic peptides |
| CN110669105B (zh) * | 2019-10-31 | 2021-06-11 | 华中科技大学 | 长效多肽构建及其抗急性肾损伤和糖尿病并发肾病的应用 |
| JP7039636B2 (ja) * | 2020-02-19 | 2022-03-22 | ソフトバンク株式会社 | システム、管理装置、監視端末、及びプログラム |
| GB202016149D0 (en) * | 2020-10-12 | 2020-11-25 | Heptares Therapeutics Ltd | Cyclic apelin receptor agonists |
| GB202016152D0 (en) * | 2020-10-12 | 2020-11-25 | Heptares Therapeutics Ltd | Linear Apelin Receptor Agonist |
| EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
| JP2025001049A (ja) * | 2021-09-01 | 2025-01-08 | 積水メディカル株式会社 | アルギニン誘導体 |
| CN116554267A (zh) * | 2022-01-30 | 2023-08-08 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇修饰的激肽或其变体和药物应用 |
| WO2024215940A1 (en) * | 2023-04-11 | 2024-10-17 | Visterra, Inc. | Apelin receptor agonists and uses thereof |
| CN119101143A (zh) * | 2023-05-31 | 2024-12-10 | 浙江大学 | 一种G蛋白偏向的apelin-13多肽突变体及应用 |
| WO2025092748A1 (zh) * | 2023-11-01 | 2025-05-08 | 拜西欧斯（北京）生物技术有限公司 | 多肽衍生物、其药物组合物及其用途 |
| WO2026007693A1 (zh) * | 2024-07-05 | 2026-01-08 | 浙江大学 | Apelin-13多肽突变体 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4351337A (en) | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US5002936A (en) | 1985-04-12 | 1991-03-26 | Seymour Lieberman | Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| WO1988001213A1 (en) | 1986-08-18 | 1988-02-25 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
| US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| NZ241954A (en) | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
| US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| CA2184002A1 (en) | 1994-02-23 | 1995-08-31 | Jeffrey M. Blaney | Method and compositions for increasing the serum half-life of pharmacologically active agents |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| AU5759399A (en) * | 1998-09-25 | 2000-04-17 | Takeda Chemical Industries Ltd. | Peptide derivative |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| JP2002533378A (ja) | 1998-12-23 | 2002-10-08 | アムジエン・インコーポレーテツド | タンパク質の徐放用ポリオール／油懸濁液 |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| JP5013152B2 (ja) | 2001-02-28 | 2012-08-29 | 株式会社ビーエムジー | 蛋白質複合体形成剤 |
| EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
| US20050054051A1 (en) | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| BRPI0213425B8 (pt) | 2001-10-19 | 2021-05-25 | Idexx Lab Inc | composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações |
| US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| GB0219512D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
| PT1641483E (pt) | 2003-06-12 | 2008-04-29 | Lilly Co Eli | Proteínas de fusão |
| CN1997356A (zh) | 2004-04-23 | 2007-07-11 | 安姆根有限公司 | 持续释放制剂 |
| JP5118969B2 (ja) | 2004-10-07 | 2013-01-16 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア | Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法 |
| WO2006076736A2 (en) * | 2005-01-14 | 2006-07-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
| US20060199812A1 (en) | 2005-01-24 | 2006-09-07 | Amgen Inc. | Method of conjugating aminothiol containing molecules to vehicles |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| AR063384A1 (es) | 2006-10-25 | 2009-01-28 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| AU2008297885A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of GLP-1 as a therapeutic agent |
| EP3385279B1 (en) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| EP2619226B1 (en) | 2010-09-22 | 2018-09-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| WO2012075037A1 (en) | 2010-11-30 | 2012-06-07 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| SI3045183T1 (sl) * | 2011-03-11 | 2018-11-30 | Genzyme Corporation | Pegiliran Apelin in njegove uporabe |
| WO2013079487A1 (en) * | 2011-11-28 | 2013-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical composition for use in the treatment of dysfunction associated with aging |
| EP2802596A1 (en) * | 2012-01-09 | 2014-11-19 | Anchor Therapeutics, Inc. | Apj receptor compounds |
| US8921307B2 (en) * | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
| JP6426107B2 (ja) * | 2012-12-20 | 2018-11-21 | アムジエン・インコーポレーテツド | Ａｐｊ受容体アゴニストおよびその使用 |
| WO2014152955A1 (en) * | 2013-03-14 | 2014-09-25 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
-
2015
- 2015-06-10 EP EP15797720.8A patent/EP3155002B1/en active Active
- 2015-06-10 US US15/317,911 patent/US10941182B2/en active Active
- 2015-06-10 MX MX2016016337A patent/MX370689B/es active IP Right Grant
- 2015-06-10 EP EP19211432.0A patent/EP3674314B8/en active Active
- 2015-06-10 CA CA2951391A patent/CA2951391C/en active Active
- 2015-06-10 WO PCT/US2015/035205 patent/WO2015191781A2/en not_active Ceased
- 2015-06-10 ES ES19211432T patent/ES2950789T3/es active Active
- 2015-06-10 EP EP23171158.1A patent/EP4257152A3/en active Pending
- 2015-06-10 AU AU2015274574A patent/AU2015274574B2/en active Active
- 2015-06-10 JP JP2016572433A patent/JP6803236B2/ja active Active
-
2019
- 2019-10-11 JP JP2019187458A patent/JP2020023539A/ja active Pending
-
2021
- 2021-01-28 US US17/160,819 patent/US11807693B2/en active Active
- 2021-12-10 JP JP2021200644A patent/JP2022028961A/ja not_active Withdrawn
-
2023
- 2023-12-13 JP JP2023210068A patent/JP2024026356A/ja active Pending
-
2024
- 2024-06-11 US US18/497,081 patent/US20240327461A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Chemically modified and conjugated antimicrobial peptides against superbugs | |
| Fominaya et al. | Strategies to stabilize cell penetrating peptides for in vivo applications | |
| Goodwin et al. | Peptides as therapeutics with enhanced bioactivity | |
| RU2008141280A (ru) | Агонисты рецептора нейромедина u и их применение | |
| JP2019501867A5 (enExample) | ||
| JP2014521684A5 (enExample) | ||
| IL277483B1 (en) | New anti-GLP-1 analogs | |
| JP2017519024A5 (enExample) | ||
| JP2011518179A5 (enExample) | ||
| JP2017522362A5 (enExample) | ||
| JP2010515686A5 (enExample) | ||
| KR20260033477A (ko) | 세포 투과 펩티드 | |
| US20130156723A1 (en) | Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof | |
| KR20220045033A (ko) | 치료용 펩티드 | |
| Khafagy et al. | Region-dependent role of cell-penetrating peptides in insulin absorption across the rat small intestinal membrane | |
| Varamini et al. | Endomorphin derivatives with improved pharmacological properties | |
| US10632187B2 (en) | Hemagglutinin-binding peptide | |
| JP2021523945A5 (enExample) | ||
| US20230234991A1 (en) | Self-assembled peptide nanorods and uses thereof | |
| US20230218710A1 (en) | Method of treating coronavirus infections | |
| Helmy et al. | Fatty Acid-Conjugated Antimicrobial Peptides: Advances in Design, Activity, and Therapeutic Potential | |
| CN104628869B (zh) | 一类兼具抗菌和抗流感病毒活性的融合肽衍生物 | |
| JPWO2017183559A1 (ja) | 薬物の経粘膜吸収促進剤 | |
| TW202233224A (zh) | 用組合療法治療纖維化之方法 | |
| JP2017500849A5 (enExample) |